AstraZeneca shares fall on reports of Bristol Myers Squibb merger talks
LONDON, August 3. AstraZeneca shares fell after reports that the company and Bristol Myers Squibb have held merger discussions over several months. Analysts described the reports as leaving them "perplexed," per the accounts.
Key takeaways
- AstraZeneca shares fell after reports that it and Bristol Myers Squibb held merger discussions over several months.
- No terms, formal offer, or deal structure were disclosed in the reports.
- Neither AstraZeneca nor Bristol Myers Squibb publicly confirmed the talks.
- Analysts were described as 'perplexed' by the reports, and no rationale for a potential combination was cited.
- Whether talks remain active or whether any formal approach has been made was not addressed.
LONDON, August 3. AstraZeneca shares fell after reports that the company and Bristol Myers Squibb have held merger discussions over several months. Analysts described the reports as leaving them "perplexed," per the accounts.
Months of reported discussions
The two companies discussed a potential combination over several months, reports said. No terms were disclosed. Neither AstraZeneca nor Bristol Myers Squibb publicly confirmed the talks.
The share price reaction at AstraZeneca followed the reports' circulation. No formal offer or deal structure appeared in the accounts.
Analyst reaction
The "perplexed" characterisation from analysts appeared in the reports alongside the news of the discussions. No rationale for a potential combination was cited. Whether talks remain active and whether any formal approach has been made were not addressed.
Note: The source provided contained only a headline and a single-sentence summary. Per editorial policy, this report reflects only what the source disclosed. No figures, terms, or additional detail were available for publication.